We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

March 27 (Reuters) - The European Patent Office declared a patent owned by CureVac (5CV.DE), opens new tab, valid, after a challenge from drugmaker BioNTech (22UAy.DE), opens new tab, the company ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...

A look at the shareholders of CureVac N.V. (NASDAQ:CVAC) can tell us which group is most powerful. With 38% stake, individual investors possess the maximum shares in the company. Put another way ...

Novo Nordisk may miss sales expectations; federal judge fines Johnson & Johnson $1.64 billion in marketing case; CureVac mRNA ...

Shares of CureVac (NASDAQ: CVAC) climbed 11% following a favorable patent validity decision in its legal proceedings against BioNTech (NASDAQ: NASDAQ: BNTX). The ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form Confirming validity of ...